Allogeneic HSCT is a pragmatic treatment option for relapsed and/or refractory AML patients; however, it seems that allogeneic HSCT cannot override the inferior outcomes conferred by the coexistence of DNMT3Amut/FLT3-ITDpos. The gene discussed is FLT3; the disease is acute myeloid leukemia.